-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chuangxiang Bio announced that the global phase 2 clinical study ASPIRE, which aims to evaluate the efficacy of izokibep in the treatment of ankylosing spondylitis, completed the first administration of the first patient in California on August 25, Beijing time.
The patient is currently in good condition
.
ASPIRE is a global randomized, double-blind, placebo-controlled Phase 2 clinical study.
It plans to enroll 300 subjects with active ankylosing spondylitis to evaluate the efficacy and safety of IMG-020
.
Chuangxiang Bio will be fully responsible for the global multi-center clinical research, including patient screening, enrollment, treatment and follow-up in the United States, China, South Korea and other countries and Taiwan
.